US › Healthcare

Atossa Genetics Inc (ATOS)

US · Healthcare · Biotechnology

$2.91+9.81%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.5M

EPS

$-0.95

EPS estimate

$-1.04

EPS came in at -0.95 against a street estimate of -1.04 — a beat of 8.7%.

Key statistics

Market cap

$26.4M

Forward P/E

7.0

P/B

0.81

Book value

$2.69

EPS (TTM)

$-4.58

52-week high

$15.45

52-week low

$1.70

50-day MA

$2.42

200-day MA

$4.37

Beta

1.27

Analyst view

Analysts rate Atossa Genetics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $19.00.

Shareholding

Insiders

1.85%

Institutions

13.61%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.62%
Ameriprise Financial Inc	2.59%
BlackRock Inc	1.65%
Renaissance Technologies Corp	1.32%
Geode Capital Management, LLC	0.93%
UBS Group AG	0.83%
Jane Street Group LLC	0.57%
Vanguard Fiduciary Trust Co	0.53%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Atossa Genetics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.